News
China regulator approval for Sulanda in non-pancreatic [extra-pancreatic] neuroendocrine tumours (epNET)- Hutchison China MediTech.
The China regulator has approved Hutchison China MediTech’s (Chi-Med’s) second internally discovered cancer drug, surufatinib (brand name Sulanda) for the treatment of epNET (non-pancreatic [extra-pancreatic] neuroendocrine tumours). Sulanda will be Chi-Med’s first unpartnered oncology drug launch in China, with potential for a label extension in pancreatic NET (pNET) later in 2021. Surufatinib is also on track to become Chi-Med’s first marketed drug in the US with the recent initiation of a rolling NDA submission for advanced NETs.
Sulanda will be launched in early 2021 by Chi-Med’s dedicated China Oncology commercial team. Label expansion following potential approval in a second indication (pNET) is expected in 2021 and would allow positioning of surufatinib as an effective treatment option for NETs irrespective of tumour origin.
Condition: Neuroendocrine Tumour
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins